Similarly, in FLT3-mutated AML, the monocytic AML cells demonstrated an increased dependency on MCL-1 instead of BCL-2, and treatment of monocytic AML with an MCL-1 inhibitor together with azacitidine significantly reduced cell survival compared to treatment with venetoclax [114]. This evidence concerns the gene MCL1 and acute myeloid leukemia.